Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has been the first-line treatment for NSCLC patients harboring activating EGFR mutations (3, 4). This evidence concerns the gene EGFR and non-small cell lung carcinoma.